AVBP Stock — ArriVent BioPharma Inc.: Cash, EV, Pipeline

Share price

$29.70

Market cap

$1,464.4M

Cash

$373.1M

Enterprise value

$1,091.3M

Balance sheet

Cash	$373.1M
Debt	$0.0M
Net cash	$373.1M
Enterprise value	$1,091.3M
Basic shares	48.3M shares
Fully diluted shares	60.1M shares
Fully diluted market cap	$1,785.4M
Cash per share	$7.72

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading AVBP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 12 - Oct 24	ARR-002	Phase 1	Ovarian Cancer; Endometrial Cancer; Platinum-resistant Ovarian Cancer (PROC)	—
Apr 12 - May 24	MRG007	Phase 1	Locally Advanced or Metastatic Solid Tumors; Colorectal Cancer; Gastric Cancer	—
Dec 12, 2028 - Jan 23, 2029	Firmonertinib	Phase 3	NSCLC; Adjuvant Treatment	—
Mar 15 - Apr 26	Firmonertinib	Phase 3	Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

firmonertinib

Phase 3 · Active Modality: tyrosine kinase inhibitor (third-generation)

Target EGFR

Partnerships Shanghai Allist Pharmaceuticals: exclusive license ex-Greater China ($40M upfront + 1,276,250 shares; $10M clinical milestones achieved to date; Joint Clinical Collaboration cost-sharing)

Indications

Non-small cell lung cancer (NSCLC) with EGFR mutations (Phase 3)

Status note Lead development candidate; R&D spend includes a Phase 3 Trials line item. No dated readout guidance stated in this filing.

ARR-002

Discovery · Active Modality: antibody-drug conjugate (ADC)

Target MUC16/NaPi2b

Partnerships Aarvik Pharmaceuticals: exclusive option exercised Aug 2024 ($1M option payment; up to $18M/product clinical+regulatory milestones, $80M/product commercial, mid-single-digit royalties)

Indications

Ovarian Cancer (Phase 1)
Endometrial Cancer (Phase 1)
Platinum-resistant Ovarian Cancer (PROC) (Phase 1)

Status note Novel tetravalent MUC16/NaPi2b-targeting ADC discovered through the Aarvik collaboration.

ARR-217

Stage not disclosed · Active Modality: antibody-drug conjugate (ADC)

Target CDH17

Partnerships Lepu Biopharma: exclusive license for GI cancers outside Greater China ($12M developmental milestones earned in 1H 2026; $1M first developmental milestone paid in Q2 2025)

Indications

Gastrointestinal cancers (Stage not disclosed)

Status note In development under the Lepu agreement; the filing states no clinical stage.

Alphamab ADC program (targets undisclosed)

Discovery · Active Modality: antibody-drug conjugate (ADC)

Partnerships Jiangsu Alphamab Biopharmaceuticals: ADC discovery collaboration (two target pairs approved; $1.2M paid per target pair selection in 1H 2025)

Indications

Cancers (Discovery)

Status note Early discovery-stage collaboration; no named candidate yet.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Firmonertinib
Lead indication	Non-Small-Cell Lung Cancer
Lead phase	Phase 3
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07185997	Phase 3	Recruiting	Sponsor	AVBP	—	Non-Small-Cell Lung Cancer; Metastatic Non-Small-Cell Lung Cancer; Advanced Non-Small-Cell Lung Cancer	—
NCT05607550	Phase 3	Active, not recruiting	Sponsor	AVBP	—	Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer; EGFR Exon 20 Mutations	—
NCT07755436	Phase 1	Recruiting	Sponsor	AVBP	—	Ovarian Cancer; Endometrial Cancer; Platinum-resistant Ovarian Cancer (PROC)	—
NCT07066657	Phase 1	Recruiting	Sponsor	AVBP	—	Locally Advanced or Metastatic Solid Tumors; Colorectal Cancer; Gastric Cancer	—
NCT05364073	Phase 1	Active, not recruiting	Sponsor	AVBP	—	Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer; Advanced Non-Small Cell Lung Cancer	—
NCT07010419	Phase 3	Recruiting	Collaborator	Allist Pharmaceuticals, Inc.	—	NSCLC; Adjuvant Treatment	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for ArriVent BioPharma, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	3,027,328	no change	1.99%	2026-08-14
Logos Global Management	1,000,000	+650,000	1.50%	2026-08-14
ADAR1 Capital Management	0	-141,814	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

AVBP — ArriVent BioPharma Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders